Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) just unveiled an update.
Wuxi XDC Cayman Inc., through its offer vehicle BioDlink International Company Limited, has launched voluntary conditional cash offers for all issued shares and outstanding share options of TOT BIOPHARM International Co. Ltd. not already owned by the offeror and its concert parties, aiming to secure a controlling stake in the Hong Kong-listed biopharmaceutical company.
As of the first closing date on 13 March 2026, the offeror had received valid acceptances representing about 46.54% of TOT BIOPHARM’s issued share capital and 85.33% of its outstanding share options, below the 60% voting rights threshold required for the share offer to become unconditional, prompting an extension of the offer period and signaling ongoing uncertainty for shareholders over the eventual change of control outcome.
The most recent analyst rating on (HK:1875) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
TOT BIOPHARM International Co. Ltd. is a biopharmaceutical company listed in Hong Kong, focused on developing and commercializing oncology-related therapies and biologic drugs. The company targets cancer treatment markets with a portfolio that includes innovative biologics and related pharmaceutical products for patients in Greater China and potentially broader international markets.
Average Trading Volume: 3,890,784
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.45B
Learn more about 1875 stock on TipRanks’ Stock Analysis page.